Journal article Open Access

First in vivo MRI study on theranostic dendrimersomes.

Filippi, Miriam; Catanzaro, Valeria; Patrucco, Deyssy; Botta, Mauro; Tei, Lorenzo; Terreno, Enzo

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="" xmlns:oai_dc="" xmlns:xsi="" xsi:schemaLocation="">
  <dc:creator>Filippi, Miriam</dc:creator>
  <dc:creator>Catanzaro, Valeria</dc:creator>
  <dc:creator>Patrucco, Deyssy</dc:creator>
  <dc:creator>Botta, Mauro</dc:creator>
  <dc:creator>Tei, Lorenzo</dc:creator>
  <dc:creator>Terreno, Enzo</dc:creator>
  <dc:description>Amphiphilic Janus-dendrimers are able to self-assemble into nanosized vesicles named dendrimersomes. We recently synthesized the 3,5-C12-EG-(OH)4 dendrimer that generates dendrimersomes with very promising safety and stability profiles, that can be loaded with different contrast agents for in vivo imaging. In this contribution, nanovesicles were loaded with both the Magnetic Resonance Imaging (MRI) reporter GdDOTAGA(C18)2 and the glucocorticoid drug Prednisolone Phosphate (PLP), in order to test their effective potential as theranostic nanocarriers on murine melanoma tumour models. The incorporation of GdDOTAGA(C18)2 into the membrane resulted in dendrimersomes with a high longitudinal relaxivity (r1=39.1mM-1s-1, at 310K and 40MHz) so that, after intravenous administration, T1-weighted MRI showed a consistent contrast enhancement in the tumour area. Furthermore, the nanovesicles encapsulated PLP with good efficiency and displayed anti-tumour activity both in vitro and in vivo, thus enabling their practical use for biomedical theranostic applications.</dc:description>
  <dc:source>Journal of Controlled Release 248 45-52</dc:source>
  <dc:subject>prednisolone phosphate</dc:subject>
  <dc:subject>magnetic resonance imaging</dc:subject>
  <dc:title>First in vivo MRI study on theranostic dendrimersomes.</dc:title>
Views 24
Downloads 44
Data volume 33.9 MB
Unique views 23
Unique downloads 44


Cite as